An FDA advisory committee voted Friday to allow compounding pharmacies to manufacture the peptides epitalon and semax, while narrowly rejecting a similar proposal for emideltide — decisions that advance Health Secretary Robert F. Kennedy Jr.’s push to expand access to unapproved peptide therapies.
The votes cap a two-day meeting that also saw the panel back four other peptides on Thursday, bringing to six the total number of compounds cleared for compounding this week. The outcomes move Kennedy one step closer to his broader goal of widening availability of peptides, short-chain amino acids that have surged in popularity through social media influencer endorsements.
Panel Splits on Emideltide
The narrow rejection of emideltide compounding stood out against an otherwise permissive session. While the committee backed epitalon and semax, the emideltide vote reflected sharper disagreement among panelists over whether the available evidence supports pharmacy-level production of that particular compound.
Compounding pharmacies operate outside the standard FDA drug approval process, custom-mixing medications that are not commercially available. Allowing these pharmacies to produce peptides means patients can access the compounds without a manufacturer going through full clinical trials and formal FDA approval.
RFK Kennedy and the MAHA Agenda
The meeting laid bare tensions between the Make America Healthy Again movement championed by Kennedy and mainstream scientists who caution against widespread use of unapproved compounds. At the core of the debate was whether it is acceptable to let individuals take medicines that have not cleared the agency’s standard safety and efficacy review.
Kennedy has made expanding access to peptides a signature element of his health agenda. The advisory panel’s recommendations, though not binding, will inform the FDA’s final decisions on which peptides compounding pharmacies may legally produce.
Peptide Popularity and Regulatory Gaps
Peptides have moved from niche clinics to mainstream wellness culture, fueled by influencer endorsements on platforms like TikTok and Instagram. Supporters argue the compounds offer benefits ranging from anti-aging to cognitive enhancement, though clinical evidence for many of these claims remains limited.
The FDA’s compounding framework exists to fill gaps when commercially approved drugs are unavailable, but the rapid rise of peptide demand has tested that system. Critics warn that allowing broader compounding could expose patients to products of inconsistent quality, while proponents argue that restricting access forces Americans toward expensive or unavailable alternatives.
What Happens Next
The FDA will now weigh the panel’s recommendations as it finalizes its compounding list. The agency typically follows advisory committee guidance but is not required to do so. Stakeholders on both sides will be watching whether officials accept the emideltide rejection or revisit the compound in future sessions.
For compounding pharmacies, the expanded list opens new production opportunities — and new compliance obligations. For patients, the decisions signal that access to peptide therapies will likely continue to widen under Kennedy’s leadership, even as the scientific debate over their risks and benefits remains unresolved.
— Aisha Mensah, health desk, AXO News